Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.51 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15993870 | 1.00 | HINT1 (0.52) | HINT1ADORA2AADORA3ADORA2BPGK1 | |
| SCHEMBL18950669 | 1.00 | HINT1 (0.52) | HINT1ADORA2AADORA3ADORA2BPGK1 | |
| SCHEMBL18950662 | 0.89 | HINT1 (0.49) | HINT1ADORA2AADORA3ADORA2BPGK1 | |
| SCHEMBL16002754 | 0.89 | HINT1 (0.49) | HINT1ADORA2AADORA3ADORA2BPGK1 | |
| SCHEMBL25269461 | 0.89 | ADORA1 (0.63) | ADORA2AADORA3ADORA2BADORA1HIF1A | |
| SCHEMBL29707951 | 0.89 | ADORA1 (0.63) | ADORA2AADORA3ADORA2BADORA1HIF1A | |
| SCHEMBL15993927 | 0.89 | ADORA1 (0.63) | ADORA2AADORA3ADORA2BADORA1HIF1A | |
| SCHEMBL18950667 | 0.86 | ADORA2A (0.57) | HINT1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL16002755 | 0.86 | ADORA2A (0.57) | HINT1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL17417838 | 0.86 | KRAS (0.52) | HINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961757-B1 | CELL-PENETRATING OLIGONUCLEOTIDES | OLIGOMER SCIENCES AB (SE) | 2017-06-14 | — | — | EP | disclosed |
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
| WO-2014131892-A1 | CELL-PENETRATING OLIGONUCLEOTIDES | OLIGOMER SCIENCES AB (SE) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | SLC29A1, SLC29A2, TYMP | HINT1 942/4885ADORA2A 28/4885ADORA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.